Brief: Bellerophon Reports Positive Top-Line Data From Phase 2 Acute Dose Escalation Study Of Inopulse For Treatment Of Pulmonary Hypertension Associated With Sarcoidosis

Bellerophon Therapeutics

17/12/2021 13:47

Dec 17 (Reuters) - Bellerophon Therapeutics Inc  BLPH.O :
    * BELLEROPHON REPORTS POSITIVE TOP-LINE DATA FROM PHASE 2
ACUTE
DOSE ESCALATION STUDY OF INOPULSE® FOR TREATMENT OF PULMONARY
HYPERTENSION ASSOCIATED WITH SARCOIDOSIS
    * BELLEROPHON THERAPEUTICS INC - PHASE 2 RESULTS PROVIDE
CLINICALLY MEANINGFUL REDUCTION IN PULMONARY VASCULAR RESISTANCE
    * BELLEROPHON THERAPEUTICS INC - INTENDS TO DESIGN
MULTI-DOSE
PHASE 2B TRIAL
    * BELLEROPHON THERAPEUTICS INC - TREATMENT WAS SAFE AND
WELL-TOLERATED
    * BELLEROPHON THERAPEUTICS INC - NO TREATMENT-EMERGENT
ADVERSE
EVENTS OBSERVED DURING ACUTE HEMODYNAMIC DOSE ESCALATION PHASE
OF STUDY

Source text for Eikon:  ID:nGNX1qW6gG 
Further company coverage:  BLPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))